{"id":"budesonide-pmdi","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":"5-10","effect":"Oral candidiasis"},{"rate":null,"effect":"Dysphonia"},{"rate":null,"effect":"Throat irritation"}]},"_chembl":{"chemblId":"CHEMBL1370","moleculeType":"Small molecule","molecularWeight":"430.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide is a selective glucocorticoid receptor agonist that acts locally in the lungs when delivered via pressurized metered-dose inhaler (pMDI). It inhibits the release of inflammatory cytokines, reduces recruitment of inflammatory cells, and decreases mucus production, thereby reducing airway inflammation and improving airflow obstruction in respiratory conditions.","oneSentence":"Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:11.493Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (maintenance and reliever therapy)"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06531798","phase":"PHASE4","title":"Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-19","conditions":"Moderate to Severe COPD","enrollment":150},{"nctId":"NCT07433569","phase":"PHASE1","title":"A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-05","conditions":"Asthma","enrollment":12},{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT07372573","phase":"NA","title":"Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-02-01","conditions":"Asthma (Diagnosis)","enrollment":210},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":"Asthma","enrollment":1038},{"nctId":"NCT06422689","phase":"PHASE4","title":"Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-05-10","conditions":"Asthma","enrollment":1507},{"nctId":"NCT04609878","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-15","conditions":"Asthma","enrollment":2274},{"nctId":"NCT04609904","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-01","conditions":"Asthma","enrollment":2187},{"nctId":"NCT03888131","phase":"PHASE3","title":"Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-07-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":750},{"nctId":"NCT06571942","phase":"PHASE4","title":"Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure","status":"RECRUITING","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2023-11-15","conditions":"COPD Bronchitis, Pollution Related Respiratory Disorder","enrollment":128},{"nctId":"NCT06482294","phase":"PHASE2","title":"CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Università degli Studi di Ferrara","startDate":"2024-06-18","conditions":"Asthma","enrollment":80},{"nctId":"NCT05219630","phase":"","title":"Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-05-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":106},{"nctId":"NCT05084222","phase":"PHASE4","title":"Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2021-11-11","conditions":"Asthma","enrollment":180},{"nctId":"NCT00476099","phase":"PHASE3","title":"Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2006-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":828},{"nctId":"NCT03197818","phase":"PHASE3","title":"Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-14","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":990},{"nctId":"NCT00915538","phase":"PHASE4","title":"Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)","status":"COMPLETED","sponsor":"Western Sky Medical Research","startDate":"2009-07","conditions":"Asthma","enrollment":16},{"nctId":"NCT00413387","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-09","conditions":"Bronchial Asthma","enrollment":219},{"nctId":"NCT02495168","phase":"PHASE3","title":"Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2017-01-13","conditions":"Asthma","enrollment":1714},{"nctId":"NCT02934607","phase":"PHASE1","title":"A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-04","conditions":"Study is Being Conducted in Healthy Volunteers","enrollment":50},{"nctId":"NCT02533505","phase":"PHASE4","title":"Phase IV O2 Consumption Study in COPD Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-25","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":51},{"nctId":"NCT02157935","phase":"PHASE3","title":"Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-27","conditions":"COPD Patients","enrollment":2026},{"nctId":"NCT02233803","phase":"PHASE4","title":"A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-14","conditions":"Asthma","enrollment":239},{"nctId":"NCT02091986","phase":"PHASE3","title":"A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04","conditions":"Asthma","enrollment":882},{"nctId":"NCT01070524","phase":"PHASE2","title":"Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-01","conditions":"Asthma","enrollment":113},{"nctId":"NCT01444430","phase":"PHASE3","title":"A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-12","conditions":"Asthma","enrollment":12460},{"nctId":"NCT02165046","phase":"PHASE1","title":"Bioavailability Study of SYN006, Pulmicort pMDI and Meptin Air in Healthy Adult.","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2012-02","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":24},{"nctId":"NCT01136382","phase":"PHASE2","title":"A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-07","conditions":"Asthma","enrollment":304},{"nctId":"NCT01360021","phase":"PHASE3","title":"New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-11","conditions":"Asthma","enrollment":214},{"nctId":"NCT01136655","phase":"PHASE2","title":"A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Asthma","enrollment":54},{"nctId":"NCT00702325","phase":"PHASE4","title":"Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Asthma","enrollment":311},{"nctId":"NCT00667992","phase":"PHASE3","title":"Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Asthma","enrollment":99},{"nctId":"NCT00419952","phase":"PHASE3","title":"A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-02","conditions":"Asthma","enrollment":742},{"nctId":"NCT00419757","phase":"PHASE3","title":"An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Asthma","enrollment":558},{"nctId":"NCT00536731","phase":"PHASE3","title":"Symbicort Rapihaler Therapeutic Equivalence Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Bronchial Asthma","enrollment":742},{"nctId":"NCT00536913","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Asthma","enrollment":107},{"nctId":"NCT00651768","phase":"PHASE3","title":"Titratable Dosing in Moderate to Severe Asthmatics","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-08","conditions":"Asthma","enrollment":570},{"nctId":"NCT00234390","phase":"PHASE4","title":"PreAsthmaControl (PAC)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"1998-11","conditions":"Asthma","enrollment":400},{"nctId":"NCT00646009","phase":"PHASE3","title":"Symbicort Onset of Action 2","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-03","conditions":"Asthma","enrollment":48},{"nctId":"NCT00646516","phase":"PHASE3","title":"Gemini Symbicort pMDI","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-10","conditions":"Mild or Moderate Asthma","enrollment":615},{"nctId":"NCT00449501","phase":"PHASE3","title":"A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-03","conditions":"Asthma","enrollment":134},{"nctId":"NCT00652392","phase":"PHASE3","title":"Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Asthma","enrollment":750},{"nctId":"NCT00646321","phase":"PHASE3","title":"Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Asthma","enrollment":540},{"nctId":"NCT00658255","phase":"PHASE2","title":"Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-10","conditions":"Stable Asthma","enrollment":175},{"nctId":"NCT00449527","phase":"PHASE3","title":"A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-03","conditions":"Asthma","enrollment":123},{"nctId":"NCT00419744","phase":"PHASE3","title":"A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1200},{"nctId":"NCT00975754","phase":"PHASE1","title":"Lung Deposition Via Different Inhalation Devices","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT00646620","phase":"PHASE3","title":"Symbicort Onset of Action 1","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Asthma","enrollment":48},{"nctId":"NCT00206154","phase":"PHASE3","title":"A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1500},{"nctId":"NCT00421122","phase":"PHASE3","title":"Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":315},{"nctId":"NCT00206167","phase":"PHASE3","title":"A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1600},{"nctId":"NCT00646594","phase":"PHASE3","title":"Atlantis Symbicort","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-11","conditions":"Asthma","enrollment":1200},{"nctId":"NCT00867737","phase":"PHASE4","title":"Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)","status":"UNKNOWN","sponsor":"Allergy and Asthma Center of El Paso","startDate":"2008-09","conditions":"Asthma","enrollment":30},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1600},{"nctId":"NCT00233584","phase":"NA","title":"Pulmicort Asthma Prevention (Post-PAC)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2001-07","conditions":"Asthma","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Budesonide pMDI","genericName":"Budesonide pMDI","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide is a small molecule glucocorticoid receptor agonist used to treat asthma. It is administered via a pressurized metered-dose inhaler (pMDI) in various formulations, including combination products with other medications.","enrichmentLevel":3,"visitCount":6,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}